Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB -3.85%25 PS Ratio is 18.52 as of Sep. 22, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 938 Biotechnology companies, Cambium Bio ranks worse than 106609.7% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cambium Bio's share price is A$0.50.
Cambium Bio's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03. Hence, Cambium Bio's PS Ratio for today is 18.52.
The historical rank and industry rank for Cambium Bio's PS Ratio or its related term are showing as below:
ASX:CMB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.41 * Ranked among companies with meaningful PS Ratio only.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cambium Bio PS Ratio Related Terms
Cambium Bio PS Ratio Historical Data
* Premium members only.
The historical data trend for Cambium Bio's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cambium Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cambium Bio's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cambium Bio's Share Price of today is A$0.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cambium Bio (ASX:CMB) has a PS Ratio of 18.52 as of Sep. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #999999 out of 938 companies in the Biotechnology industry.
Is Cambium Bio's PS Ratio too high?
Cambium Bio's current PS Ratio is 18.52. The Biotechnology industry median PS Ratio is 9.41. Cambium Bio's value of 18.52 is 96.8% above this industry median. Based on the distribution chart, Cambium Bio ranks #999999 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 938 companies for PS Ratio. This places Cambium Bio in the lower half of its industry. The industry median PS Ratio is 9.41. Cambium Bio's value of 18.52 is 96.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambium Bio's current PS Ratio of 18.52 is 96.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current PS Ratio is 18.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current PS Ratio of 18.52. The current PS Ratio is 18.52 and 96.8% above the Biotechnology industry median of 9.41. Cambium Bio's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current PS Ratio is 18.52 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
25GF Score
Get the complete analysis for ASX:CMB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
